Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794
Subjects:
Myelodysplastic Syndromes
(MeSH)
Leukemia, Myeloid, Acute
(MeSH)
Acute Myeloid Leukemia
(OpenAlex Topic)
Efficacy and Resistance in CML Treatment
(OpenAlex Topic)
Molecular Pathogenesis of Myeloproliferative Disorders
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1200/jco.22.01794
PMID:
DOI:
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: